|
|
 |
|
Viewing report
|
|
|
|
Cardiology - Acute Coronary Syndrome, Anticoagulants
Medpredict, May 2008, Pages: 156
This report provides in-depth analysis of the market and pipeline from the perspective of global thought leaders.
This report is based on a series of seven full interviews with US Thought Leaders (emergency medicine, orthopedic surgery, interventional cardiology, electrophysiology), and supporting comments from our last interventional CV report (January 2008). This Panel convened shortly after ACC 2008. In an era of greater restrictions on detailing to physicians we asked our Panel to outline the differences that they see in reps who market drugs and devices. The Panel provided general comments and specific real-world examples on how hospital-based reps are influencing their prescribing behavior.
One of the key drawbacks to warfarin is the need for INR monitoring. The Panel discusses the new in-home INR options.
The Panel next focused on the role of interventional and medical therapy in acute coronary syndrome. The discussion covered a broad array of stents (drug eluting vs. bare metal) and anticoagulants and their interplay in the emergency room, the cath lab, the EP lab, the orthopedic surgical theater and the post-hospital environment. Each Panelist shares a perspective on the balance between restenosis, anticoagulant effects, risks of DVT/PE and bleeding.
In order to understand the issues surrounding post-operative surgical bleeding, we also spoke with an orthopedic surgeon specializing in “high profile injuries” for a number of major US sports teams. Finally, we received input into a variety of devices and new drugs targeting atrial arrhythmias
The drugs discussed by the Panel include: Lovenox (enoxaparin; Sanofi-Aventis), Arixtra (fondaparinux; GSK), Coumadin (warfarin; BMS), Exanta (ximelagatran; AstraZeneca), Pradaxa (dabigatran; Boehringer Ingelheim), Xarelto (rivaroxaban; Bayer, J&J), idraparinux (Sanofi-Aventis), SSR-126517
(Sanofi-Aventis), apixaban (BMS / Pfizer), YM-150 (Astellas), betrixaban (PRT054021; Portola), DU-176b (Daiichi Sankyo), AZD0837 (AstraZeneca), PD-0348292 (Pfizer), otamixaban (Sanofi-Aventis), LY517717 (Lilly), flovagatran (TGN 255; Trigen), Angiomax (bivalirudin; The Medicines Company), AVE-5026 (Sanofi-Aventis), Plavix (clopidogrel; S-A, BMS), Aggrenox (aspirin/dipyridamole; Boehringer-Ingelheim), Effient (prasugrel; Daiichi Sankyo / Lilly), cangrelor (The Medicines Company); ticagrelor (AZD-6140; AstraZeneca), SCH530348 (Thrombin Receptor Antagonist; Schering-Plough), DZ-697b (Daiichi-Sankyo), Ranexa (ranolazine; CV Therapeutics), Micardis (telmisartan), Multaq (dronedarone; Sanofi-Aventis), Kynapid (vernakalant; Astellas/Cardiome), azimilide (Procter & Gamble), Cypher (Cordis), Taxus (Boston Scientific), Endeavor (Zotarolimus-Eluting Coronary Stent; Medtronic), Xience Vision (Abbott) ; Promus (Boston Scientific), Export (Medtronic), Pronto (Vascular Solutions), AngioJet (Possis), Helex Septal Occluder (Gore), INRatio (Hemosense/Inverness), CoaguChek XS (Roche), Laser Ablation (Cardio Focus), GENius™ RF Multi-Channel generator (Ablation Frontiers), Mesh Electrode (Bard), Arctic Front (CryoCath Technologies), PLAATO™ System (ev3), WATCHMAN LAA (Atritech)
Customers who bought this item also bought
sanofi-aventis - Pipeline - Products - Performance - Potential
Sanofi-Aventis: PharmaVitae Profile
Sanofi-Aventis
Commercial Insight: Antithrombotics - Sanofi-Aventis the Dominant Player
Sanofi-Aventis: PharmaVitae Model
Anticoagulants - A Global Market Review
Anticoagulants - Global Strategic Business Report
Daiichi Sankyo Co., Ltd: PharmaVitae Profile
Sanofi-Aventis Partnering Guide 2008
Sanofi-Aventis SA and Regeneron Pharmaceuticals, Inc. Strategic Agreement Call - Sanofi-Aventis SA - Earnings Transcript
Daiichi Sankyo Company Limited
Sanofi-Aventis: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
|
|
|
|
